In Reply We thank Moretto et al for their interest in our study.1 As the authors correctly suspected, only a small fraction of the patient population (7 patients) received preoperative fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI); the introduction of this regimen is a fairly recent development that is not well represented in our cohort, which stretches back to 2000. Moreover, only 1 patient treated with FOLFOXIRI had a non-V600E BRAF mutation while the remaining 6 had V600E BRAF mutations, leaving little room for codon/point-specific stratification.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Margonis GA, Andreatos N, Weiss MJ. BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases—Reply. JAMA Surg. 2018;153(12):1163–1164. doi:10.1001/jamasurg.2018.3339
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.